COVID rebound after Pfizer treatment likely due to robust immune response, study finds

  • In US
  • 2022-10-06 19:48:49Z
  • By Reuters

By Leroy Leo and Julie Steenhuysen

(Reuters) - A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday.

They concluded that taking a longer course of the drug - beyond the recommended five days - was not required to reduce the risk of a recurrence of symptoms as some have suggested, based on an intensive investigation of rebound in eight patients at the National Institutes of Health's Clinical Center.

All patients in the study had developed robust immune responses, but researchers found higher levels of antibodies in the patients who experienced a rebound.

The team said their data argues against the hypothesis that impaired immune responses are the reason symptoms return in some patients.

"Our findings suggest that a more robust immune response rather than uncontrolled viral replication characterizes these clinical rebounds," the team wrote.

The study, published in the journal Clinical Infectious Diseases, followed numerous reports of individuals who took Paxlovid as recommended within five days of infection and saw a return of symptoms after they completed the five-day course of treatment.

President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced a COVID rebound after taking the medicine.

The cases raised concerns that Pfizer's two-drug antiviral treatment could interfere with development of a long-lasting immune response.

The study involved six people whose COVID symptoms returned after taking Paxlovid, and two with rebound symptoms after apparent recovery who did not take the pills. Their responses were compared to a group of six people who had COVID but did not experience a rebound. All volunteers had been vaccinated and boosted and all were infected with some version of the Omicron variant of the virus.

Blood from study volunteers underwent intensive investigation to assess their immune response during the acute infection phase and the rebound phase.

All of the rebound patients had experienced significant improvement in their symptoms before their rebound. Of those who had a rebound after Paxlovid, four had milder symptoms than during their initial infection, one had the same level of severity and one reported worse symptoms.

None of the rebound patients required additional treatment or hospitalization.

Rebound symptoms may be partially driven by a robust immune response to residual virus in the respiratory tract, the study authors suggested. They concluded that the drug does not impede the immune response in some individuals, as some had feared.

Larger and more detailed studies are needed to further understand COVID symptom rebound, the research team said, adding that the current data supports the need for isolation of such patients.

The researchers also suggested that there is still a need to evaluate longer courses of Paxlovid in immunocompromised individuals where the immune response may be ineffective.

(Reporting by Leroy Leo in Bengaluru and Julie Steenhuysen in Chicago; Editing by Bill Berkrot)


More Related News

Britain's health regulator backs COVID vaccine for infants from six months
  • US
  • 2022-12-06 11:33:54Z

LONDON (Reuters) -Britain's health regulator on Tuesday authorised a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating...

Chinese rush to stock up antigen kits, medicines as COVID prevention curbs ease
Chinese rush to stock up antigen kits, medicines as COVID prevention curbs ease
  • US
  • 2022-12-06 09:12:34Z

Chinese residents have rushed to snap up COVID-19 antigen kits and medicines for fevers and colds, as the country's recent easing of prevention measures...

China Covid: Xi
China Covid: Xi's face-saving exit from his signature policy

If you want to know what the government's plan is, look at what it does rather than what it says.

Investors bet China
Investors bet China's rally on easing COVID curbs will be furious but fleeting

Investors piling into China's tourism, catering and beverage stocks as Beijing eases strict COVID-19 curbs are also keeping an eye on the exits, factoring in...

China's patchy COVID easing sows confusion but comforts investors
  • US
  • 2022-12-05 04:04:54Z

BEIJING (Reuters) -A partial easing of the world's toughest COVID-19 curbs sowed confusion across China on Monday, even as global investors cheered the...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: US